{"id":"NCT02128763","sponsor":"University of Pennsylvania","briefTitle":"Dry Eye Assessment and Management Study","officialTitle":"Dry Eye Assessment and Management Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2017-09-05","completion":"2020-01-31","firstPosted":"2014-05-01","resultsPosted":"2019-01-04","lastUpdate":"2022-07-19"},"enrollment":535,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"Omega-3 supplements","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Omega-3 supplements","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.","primaryOutcome":{"measure":"Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months","timeFrame":"12 months","effectByArm":[{"arm":"Omega-3 Supplements","deltaMin":-13.9,"sd":15.6},{"arm":"Placebo (5 Gms of Refined Olive Oil/Day)","deltaMin":-12.5,"sd":18.2}],"pValues":[{"comp":"OG000 vs OG001","p":"0.40"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["30161055","31022469","31445751","31489258","32097181","32821497","39079754","38391283","38345056","36575626","34294637","33290317","31425752","31116166","29883769","29652551"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":349},"commonTop":[]}}